🚀 Pharmidex Unveils Its Cutting-Edge In Silico Drug Discovery Platform! 🧬💻
February 24, 2025

At Pharmidex, we are revolutionizing drug discovery with our state-of-the-art in silico platform (https://lnkd.in/eibfwguP), accelerating the path from target identification to lead optimization with precision and efficiency.

🔬 What sets our platform apart?
âś… AI-driven target identification & protein structure analysis
âś… Advanced molecular docking for high-affinity ligand screening
âś… 3D pharmacophore modeling for enhanced drug design
âś… Seamless integration of predictive simulations & real-world validation

Our approach combines cutting-edge computational tools with deep scientific expertise to de-risk drug development and fast-track novel therapeutics for a healthier future.

📽️ Watch our latest video(1/5) showcasing the power of our technology, starting from Determination of target structures and Determination of ligands

📩 Ready to transform your drug discovery journey? Let’s collaborate!

May 8, 2025
At Pharmidex, we are proud to contribute to scientific innovation through robust and reliable bioanalytical support from early discovery to regulated studies. For over eight years, we've partnered with Shimadzu, using their LCMS-8060 and LC-2050 systems to deliver high-quality, data-driven results tailored to diverse client needs. Their instruments have played a key role in advancing our bioanalytical capabilities and supporting the success of our collaborative projects. Our Head of Operations, Ash Alavijeh , recently shared insights from our long-standing collaboration as part of Shimadzu’s 150th anniversary testimonial series. We are honored to be part of their journey and look forward to continuing this partnership built on shared values of precision, reliability, and innovation. 👉 Read more stories from the Shimadzu global community here .
May 7, 2025
At Pharmidex, we stand in solidarity with individuals and families affected by Huntington’s Disease a rare, inherited neurodegenerative condition that impacts the mind, body, and spirit. Throughout May, we reaffirm our commitment to advancing neuroscience research and supporting drug discovery efforts aimed at neurodegenerative diseases. Our team is proud to collaborate with partners working toward meaningful therapies that can improve quality of life and bring hope to the HD community. Let’s raise awareness. Let’s drive innovation. Let’s stand together.
C3 Summit London
May 5, 2025
We’re pleased to share that Mo Yaqoob from our Business Development team will be attending the C3 Summit on 8 May 2025 at 8 Northumberland Ave, London. 🔗 https://www.thec3summit.com/london-2025/  Mo is looking forward to meeting fellow attendees, exploring new partnerships, and discussing how we can work together to accelerate the development of innovative drug candidates. If you're attending, don’t hesitate to connect let’s spark the next great collaboration!
More Posts